Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment in Patients with Advanced or Recurrent Endometrial Cancer in Spain.

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Astrazeneca Farmaceutica Spain S.A.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Female

Therapeutic area

Diseases [C] - Neoplasms [C04]

Trial duration

30 Dec 2024 → ongoing

Decision date (initial)

2024-11-04

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

AstraZeneca Farmacéutica Spain S.A.

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Therapy, Safety, Efficacy

To describe safety profile of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC.

Secondary objectives 2

1. To describe effectiveness of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC.
2. To describe the impact of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line treatment for patients with pMMR aEC on patients’ Health Related Quality of Life (HRQoL) and (PROs).

Conditions and MedDRA coding

Advanced or recurrent endometrial cancer

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 11

1. Women ≥18 years at the time of screening.
2. Informed consent form provided by patient (or a legally acceptable representative), including the biomarker research component of the study.
3. Histologically confirmed diagnosis of endometrial carcinoma (all histologies, including carcinosarcoma) with archival or recent biopsy available to send at study entry.
4. Only patients with pMMR tumors are allowed (mismatch repair status determined locally per current clinical practice).
5. Patients must have endometrial cancer in one of the following categories: a) Newly diagnosed Stage III disease classified by FIGO 2023 with mesurable disease per RECIST 1.1 following surgery or diagnostic biopsy. b) Newly diagnosed Stage IV disease classified by FIGO 2023. Patients with primary cytoreduction without residual disease are allowed. c) Recurrence of disease where the potential for cure by surgery alone or in combination is poor.
6. Naïve to first-line systemic anti-cancer treatment. For patients with recurrent disease, prior systemic anti-cancer treatment is allowed only if it was administered in the adjuvant setting (for patients with FIGO 2023 stage II, III or IVA) and there is at least 6 months from date of last dose of adjuvant systemic treatment to date of subsequent relapse
7. At least one, but ideally two FFPE tumour sample block must be available and must be suitable for NGS and IHC evaluation by central lab. Preferably from primary endometrial tumor, but also from metastatic site will be allowed if there is no primary tumor block available. Tumor tissue has to have no less than 30% tumoral cell and tumoral area size has to be no less than 0,5cm2
8. Eastern Cooperative Oncology Group (ECOG)/ World Health Organisation (WHO) performance status ≤ 2 at enrolment. Note: not more than 20% of patients with ECOG PS2 will be allowed; once this limit is met, additional enrolled patients must have PS <2.
9. Postmenopausal or evidence of nonchildbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of Cycle 1 Day 1 and confirmed prior to treatment on Cycle 1 Day 1. Women will be considered post - menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. The following age-specific requirements apply: - Women <50 years of age will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments, and if they have LH and FSH levels in the post- menopausal range for the institution. - Women ≥50 years of age will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago. - Women who are surgically sterile (ie, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) are eligible.
10. Adequate organ and bone marrow function, defined as: − Haemoglobin ≥10.0 g/dL − Absolute neutrophil count (ANC) ≥1.5 × 109/L − Platelet count ≥100 × 109/L − Serum bilirubin ≤1.5 × the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome, who will be allowed in consultation with their physician. − Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; for patients with hepatic metastases, ALT and AST ≤5 × ULN.
11. Measured creatinine clearance (CrCL) >51 mL/min or calculated CrCL >51 mL/min as determined by Cockcroft-Gault (using actual body weight), a 24-hour urine test or another validated test as per local practice: Estimated CrCL = (140-age [years]) × weight (kg) × 0.85 (mL/min) 72 × serum creatinine (mg/dL)

Exclusion criteria 28

1. Any unresolved toxicity National Cancer Institute Common Terminology Criteria for Adverse Event (NCI CTCAE version 5.0) Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. Note: − Patients with Grade ≥2 neuropathy may be included only after consultation with the study physician. − Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or olaparib may be included only after consultation with the study physician.
2. Uterine sarcomas will not be allowed.
3. Major surgical procedure (as defined by the investigator) within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery. Note: Local surgery of isolated lesions for palliative intent is acceptable or diagnostic staging.
4. History of allogenic organ transplantation.
5. Previous allogenic bone marrow transplant or double umbilical cord blood transplantation.
6. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn’s disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves’ disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion: − Patients with vitiligo or alopecia. − Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement. − Any chronic skin condition that does not require systemic therapy. − Patients without active disease in the last 5 years may be included but only after consultation with the study physician. − Patients with coeliac disease controlled by diet alone.
7. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension (systolic blood pressure >160 mmHg; diastolic blood pressure >100 mmHg), unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (ILD), serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
8. History of another primary malignancy except for: − Malignancy treated with curative intent and with no known active disease. − ≥5 years before the first dose of IP and of low potential risk for recurrence. − Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. − Adequately treated carcinoma in situ without evidence of disease.
9. History of leptomeningeal carcinomatosis
10. Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have a magnetic resonance imaging (MRI) (preferred) or computed tomography (CT) each preferably with IV contrast of the brain prior to study entry.
11. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischaemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation ≥500 ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome
12. History of active primary immunodeficiency.
13. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive HBV surface antigen [HbsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HbsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
14. Myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML
15. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study drug.
16. Prior treatment with PARP inhibitors.
17. Any prior exposure to immune-mediated therapy, including (but not limited to) other anti CTLA-4, anti-PD-1, anti-PD-L1, or anti–programmed-cell-death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
18. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable. Prior hormonal therapy for cancer treatment must be stopped at least 7 days prior to first dose of study treatment.
19. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion: − Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) − Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent. − Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
20. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
21. Concomitant use of known strong CYP3A inhibitors (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg, ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting study treatment is 2 weeks.
22. Concomitant use of known strong (e.g., phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John’s Wort) or moderate CYP3A inducers (e.g., bosentan, efavirenz, modafinil). The required washout period prior to starting study treatment is 5 weeks for phenobarbital and 3 weeks for other agents.
23. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
24. Unable to swallow orally administered medication.
25. Any gastrointestinal disorder likely to interfere with absorption of the study medication.
26. Pregnant or breastfeeding.
27. Patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after last dose of study intervention or 6 months after the last dose of olaparib, whichever is later.
28. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 3

1. Frequency of AEs that lead to treatment dose changes, temporary interruptions, or permanent discontinuation
2. Frequency of Immune-mediated adverse events1 (imAEs).
3. Frequency of grade ≥3 AEs. [Timeframe: 12 months after LSI]

Secondary endpoints 6

1. Progression Free Survival (PFS) defined as the time from the date of first dose of treatment2 until the date of objective disease progression or death (by any cause in the absence of progression). The measure of interest is the median PFS.
2. Objective Response Rate (ORR) using site investigator assessments according to RECIST 1.1.
3. Duration of Response (DoR) defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression or death in the absence of disease progression. The measure of interest is the median DoR.
4. Overall Survival (OS) defined as the time from the date of first dose of treatment2 until death from any cause. The measure of interest is the median OS.
5. Change from baseline in score on EORTC QLQ-C30 and EORTC QLQ-EN24 reported at enrollment and then throughout the prospective study follow-up to end of study treatment: every 12 weeks, at the end of treatment and at progression if the EOT is other reason than progression
6. Percentage of patients having clinically meaningful deterioration (i.e., absolute change in the score from baseline of ≥10) at 6, 12, 24 and 36 months after LSI.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 3

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Astrazeneca Farmaceutica Spain S.A.

Sponsor organisation

Astrazeneca Farmaceutica Spain S.A.

Address

Calle Del Puerto De Somport 21-23, Poligono Industrial Carretera De Burgos Poligono Industrial Carretera De Burgos

City

Madrid

Postcode

28050

Country

Spain

Scientific contact point

Organisation

Astrazeneca Farmaceutica Spain S.A.

Contact name

Luciana Ester Baez

Public contact point

Organisation

Astrazeneca Farmaceutica Spain S.A.

Contact name

AstraZeneca Clinical Study Information Center

Third parties 2

Locations

1 EU/EEA country · 24 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 5 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications